Barclays Initiates Coverage of Cytokinetics (CYTK) with Overweight Recommendation - Nasdaq
23 hours ago • Google News
Cytokinetics Inc (CYTK)
US$ 40.336.13%
Price Chart
Key Statistics
Market Cap
$ 4.81B
P/E Ratio
0.00
Revenue (TTM)
$ 18.47M
Volume
1.4M
52W High
$ 68.44
52W Low
$ 32.74
Dividend Yield
0.00%
Beta
0.94
Technicals
50-Day MA
42.5644
200-Day MA
50.117
52 Week High
68.44
52 Week Low
32.74
About CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating di.
Employees
498
Headquarters
South San Francisco, CA
CEO
Mr. Robert I. Blum
Latest News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg